Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1994 Mar;49(3):233–239. doi: 10.1136/thx.49.3.233

Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.

T K Rogers 1, W Sheedy 1, J Waterhouse 1, P Howard 1, A H Morice 1
PMCID: PMC1021151  PMID: 8202879

Abstract

BACKGROUND--Pulmonary artery pressure is elevated in patients with advanced chronic obstructive pulmonary disease (COPD). Release of atrial natriuretic peptide (ANP) is increased in pulmonary hypertension and this hormone may both selectively vasodilate pulmonary vessels and inhibit pulmonary vascular remodelling. The hypothesis that ANP has a physiological role in protection of the pulmonary circulation from pressure overload, and that it may be beneficial in patients with COPD, has been examined. METHODS--Ten patients with hypoxic COPD were infused for 30 minute periods with saline followed by ANP at 0.4, 2, and 10 pmol/kg/min respectively via a pulmonary artery catheter whilst monitoring haemodynamics and oxygenation. RESULTS--Levels of immunoreactive ANP (irANP) increased from a mean (SD) of 23 (15) pmol/l to a maximum of 94 (41) pmol/l. Neither systemic blood pressure, cardiac output nor total systemic vascular resistance showed any correlation with irANP levels. There were negative correlations between levels of ANP and mean pulmonary artery pressure which fell from 28.7 to 25.9 mm Hg, pulmonary artery wedge pressure which fell from 6.5 to 4.6 mmHg, and total pulmonary vascular resistance which fell from 489 to 428 dynes s cm-5. There was a small fall in PaCO2 from 6.2 to 5.9 kPa, whilst venous admixture and oxygen delivery both increased non-significantly. CONCLUSIONS--At these pathophysiological concentrations there was evidence that ANP selectively reduced right ventricular afterload. These data support the hypotheses that increased plasma levels of ANP may be beneficial in hypoxic COPD, and that endogenous ANP may ameliorate pulmonary hypertension in humans.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abell T. J., Richards A. M., Ikram H., Espiner E. A., Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem Biophys Res Commun. 1989 May 15;160(3):1392–1396. doi: 10.1016/s0006-291x(89)80158-5. [DOI] [PubMed] [Google Scholar]
  2. Adams S. P. Structure and biologic properties of the atrial natriuretic peptides. Endocrinol Metab Clin North Am. 1987 Mar;16(1):1–17. [PubMed] [Google Scholar]
  3. Adnot S., Andrivet P., Chabrier P. E., Piquet J., Plas P., Braquet P., Roudot-Thoraval F., Brun-Buisson C. Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion. J Clin Invest. 1989 Mar;83(3):986–993. doi: 10.1172/JCI113985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Adnot S., Chabrier P. E., Andrivet P., Viossat I., Piquet J., Brun-Buisson C., Gutkowska Y., Braquet P. Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension. Am Rev Respir Dis. 1987 Oct;136(4):951–956. doi: 10.1164/ajrccm/136.4.951. [DOI] [PubMed] [Google Scholar]
  5. Adnot S., Chabrier P. E., Brun-Buisson C., Viossat I., Braquet P. Atrial natriuretic factor attenuates the pulmonary pressor response to hypoxia. J Appl Physiol (1985) 1988 Nov;65(5):1975–1983. doi: 10.1152/jappl.1988.65.5.1975. [DOI] [PubMed] [Google Scholar]
  6. Agostoni P., Doria E., Galli C., Tamborini G., Guazzi M. D. Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989 Jan;139(1):120–125. doi: 10.1164/ajrccm/139.1.120. [DOI] [PubMed] [Google Scholar]
  7. Bratel T., Hedenstierna G., Nyquist O., Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. Eur Respir J. 1990 Jan;3(1):46–54. [PubMed] [Google Scholar]
  8. Brent B. N., Berger H. J., Matthay R. A., Mahler D., Pytlik L., Zaret B. L. Contrasting acute effects of vasodilators (nitroglycerin, nitroprusside, and hydralazine) on right ventricular performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: a combined radionuclide-hemodynamic study. Am J Cardiol. 1983 Jun;51(10):1682–1689. doi: 10.1016/0002-9149(83)90210-2. [DOI] [PubMed] [Google Scholar]
  9. Cody R. J., Atlas S. A., Laragh J. H., Kubo S. H., Covit A. B., Ryman K. S., Shaknovich A., Pondolfino K., Clark M., Camargo M. J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov;78(5):1362–1374. doi: 10.1172/JCI112723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goy J. J., Waeber B., Nussberger J., Bidiville J., Biollaz J., Nicod P., Mooser V., Kappenberger L., Brunner H. R. Infusion of atrial natriuretic peptide to patients with congestive heart failure. J Cardiovasc Pharmacol. 1988;12(5):562–570. doi: 10.1097/00005344-198811000-00010. [DOI] [PubMed] [Google Scholar]
  11. Groban L., Ebert T. J., Kreis D. U., Skelton M. M., Van Wynsberghe D. M., Cowley A. W., Jr Hemodynamic, renal, and hormonal responses to incremental ANF infusions in humans. Am J Physiol. 1989 May;256(5 Pt 2):F780–F786. doi: 10.1152/ajprenal.1989.256.5.F780. [DOI] [PubMed] [Google Scholar]
  12. Herrmann H. C., Rosenthal A. D., Davis C. A. Cardiovascular effects of intracoronary atrial natriuretic peptide administration in man. Am Heart J. 1990 Aug;120(2):308–315. doi: 10.1016/0002-8703(90)90074-8. [DOI] [PubMed] [Google Scholar]
  13. Howard P. Vasodilator drugs in chronic obstructive airways disease. Eur Respir J Suppl. 1989 Jul;7:678s–681s. [PubMed] [Google Scholar]
  14. Jansen T. L., Morice A. H., Brown M. J. A comparison of the vasodilator responses to atrial peptides in the pulmonary and renal arteries of the pig in vitro. Br J Pharmacol. 1987 Jul;91(3):687–691. doi: 10.1111/j.1476-5381.1987.tb11263.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jin H., Yang R. H., Chen Y. F., Jackson R. M., Oparil S. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J Clin Invest. 1990 Jan;85(1):115–120. doi: 10.1172/JCI114400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kokubu T., Nagae A., Hiwada K., Kazatani Y., Joh T., Matsuo H. Pulmonary arterial pressure and plasma concentration of atrial natriuretic factor (ANF) in patients with heart disease. Jpn Heart J. 1986 Nov;27(6):791–796. doi: 10.1536/ihj.27.791. [DOI] [PubMed] [Google Scholar]
  17. Labat C., Norel X., Benveniste J., Brink C. Vasorelaxant effects of atrial peptide II on isolated human pulmonary muscle preparations. Eur J Pharmacol. 1988 Jun 10;150(3):397–400. doi: 10.1016/0014-2999(88)90027-1. [DOI] [PubMed] [Google Scholar]
  18. Lindberg F., Andersson K. E. Vasodilator responses to alpha-human-atrial natriuretic peptide in isolated omental and pulmonary arteries from rabbit and man. Acta Physiol Scand. 1988 Nov;134(3):391–397. doi: 10.1111/j.1748-1716.1988.tb08506.x. [DOI] [PubMed] [Google Scholar]
  19. MacNee W., Wathen C. G., Hannan W. J., Flenley D. C., Muir A. L. Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale. Br Med J (Clin Res Ed) 1983 Oct 22;287(6400):1169–1172. doi: 10.1136/bmj.287.6400.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Matthay R. A., Niederman M. S., Wiedemann H. P. Cardiovascular-pulmonary interaction in chronic obstructive pulmonary disease with special reference to the pathogenesis and management of cor pulmonale. Med Clin North Am. 1990 May;74(3):571–618. doi: 10.1016/s0025-7125(16)30541-7. [DOI] [PubMed] [Google Scholar]
  21. Mitaka C., Hirata Y., Nagura T., Sakanishi N., Tsunoda Y., Amaha K. Plasma alpha-human atrial natriuretic peptide concentration in patients with acute lung injury. Am Rev Respir Dis. 1992 Jul;146(1):43–46. doi: 10.1164/ajrccm/146.1.43. [DOI] [PubMed] [Google Scholar]
  22. Morice A. H., Pepke-Zaba J., Brown M. J., Thomas P. S., Higenbottam T. W. Atrial natriuretic peptide in primary pulmonary hypertension. Eur Respir J. 1990 Sep;3(8):910–913. [PubMed] [Google Scholar]
  23. Morice A., Pepke-Zaba J., Loysen E., Lapworth R., Ashby M., Higenbottam T., Brown M. Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man. Clin Sci (Lond) 1988 Apr;74(4):359–363. doi: 10.1042/cs0740359. [DOI] [PubMed] [Google Scholar]
  24. Münzel T., Drexler H., Holtz J., Kurtz S., Just H. Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure. Circulation. 1991 Jan;83(1):191–201. doi: 10.1161/01.cir.83.1.191. [DOI] [PubMed] [Google Scholar]
  25. Neilly J. B., Carter R., Tweddel A., Martin W., Hutton I., Banham S. W., Stevenson R. D. Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD. Respir Med. 1989 Jan;83(1):59–65. doi: 10.1016/s0954-6111(89)80061-7. [DOI] [PubMed] [Google Scholar]
  26. Numan N. A., Gillespie M. N., Altiere R. J. Pulmonary vasorelaxant activity of atrial peptides. Pulm Pharmacol. 1990;3(1):29–33. doi: 10.1016/0952-0600(90)90006-5. [DOI] [PubMed] [Google Scholar]
  27. Ou L. C., Sardella G. L., Hill N. S., Thron C. D. Does atrial natriuretic factor protect against right ventricular overload? I. Hemodynamic study. J Appl Physiol (1985) 1989 Oct;67(4):1606–1611. doi: 10.1152/jappl.1989.67.4.1606. [DOI] [PubMed] [Google Scholar]
  28. Poels L. G., Peters D., van Megen Y., Vooijs G. P., Verheyen R. N., Willemen A., van Niekerk C. C., Jap P. H., Mungyer G., Kenemans P. Monoclonal antibody against human ovarian tumor-associated antigens. J Natl Cancer Inst. 1986 May;76(5):781–791. [PubMed] [Google Scholar]
  29. Raffestin B., Levame M., Eddahibi S., Viossat I., Braquet P., Chabrier P. E., Cantin M., Adnot S. Pulmonary vasodilatory action of endogenous atrial natriuretic factor in rats with hypoxic pulmonary hypertension. Effects of monoclonal atrial natriuretic factor antibody. Circ Res. 1992 Jan;70(1):184–192. doi: 10.1161/01.res.70.1.184. [DOI] [PubMed] [Google Scholar]
  30. Richards A. M., Wittert G., Espiner E. A., Yandle T. G., Frampton C., Ikram H. EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide. J Clin Endocrinol Metab. 1991 Jun;72(6):1317–1322. doi: 10.1210/jcem-72-6-1317. [DOI] [PubMed] [Google Scholar]
  31. Rogers T. K., Stewart A. G., Morice A. H. Effect of chronic hypoxia on rat pulmonary resistance vessels: vasodilatation by atrial natriuretic peptide. Clin Sci (Lond) 1992 Dec;83(6):723–729. doi: 10.1042/cs0830723. [DOI] [PubMed] [Google Scholar]
  32. Sakamoto M., Nakao K., Morii N., Sugawara A., Yamada T., Itoh H., Shiono S., Saito Y., Imura H. The lung as a possible target organ for atrial natriuretic polypeptide secreted from the heart. Biochem Biophys Res Commun. 1986 Mar 13;135(2):515–520. doi: 10.1016/0006-291x(86)90024-0. [DOI] [PubMed] [Google Scholar]
  33. Seibold H., Bunjes D., Schmidt A., Hombach V. Pathophysiological aspects of predominant preload lowering on pulmonary circulation, gas exchange, and the biventricular function in patients with chronic obstructive lung disease. Clin Cardiol. 1988 Sep;11(9):630–638. doi: 10.1002/clc.4960110908. [DOI] [PubMed] [Google Scholar]
  34. Spiro S. G., Hahn H. L., Edwards R. H., Pride N. B. An analysis of the physiological strain of submaximal exercise in patients with chronic obstructive bronchitis. Thorax. 1975 Aug;30(4):415–425. doi: 10.1136/thx.30.4.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Stewart A. G., Bardsley P. A., Baudouin S. V., Waterhouse J. C., Thompson J. S., Morice A. H., Howard P. Changes in atrial natriuretic peptide concentrations during intravenous saline infusion in hypoxic cor pulmonale. Thorax. 1991 Nov;46(11):829–834. doi: 10.1136/thx.46.11.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stewart A. G., Sheedy W., Thompson J. S., Morice A. H. Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling. Pulm Pharmacol. 1992 Jun;5(2):111–114. doi: 10.1016/0952-0600(92)90027-e. [DOI] [PubMed] [Google Scholar]
  37. Stewart A. G., Thompson J. S., Rogers T. K., Morice A. H. Atrial natriuretic peptide-induced relaxation of pre-constricted isolated rat perfused lungs: a comparison in control and hypoxia-adapted animals. Clin Sci (Lond) 1991 Aug;81(2):201–208. doi: 10.1042/cs0810201. [DOI] [PubMed] [Google Scholar]
  38. Ude A. C., Howard P. Controlled oxygen therapy and pulmonary heart failure. Thorax. 1971 Sep;26(5):572–578. doi: 10.1136/thx.26.5.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Westendorp R. G., Roos A. N., van der Hoeven H. G., Tjiong M. Y., Simons R., Frölich M., Souverijn J. H., Meinders A. E. Atrial natriuretic peptide improves pulmonary gas exchange in subjects exposed to hypoxia. Am Rev Respir Dis. 1993 Aug;148(2):304–309. doi: 10.1164/ajrccm/148.2.304. [DOI] [PubMed] [Google Scholar]
  40. Westendorp R. G., Roos A. N., van der Hoeven H. G., Tjiong M. Y., Simons R., Frölich M., Souverijn J. H., Meinders A. E. Atrial natriuretic peptide improves pulmonary gas exchange in subjects exposed to hypoxia. Am Rev Respir Dis. 1993 Aug;148(2):304–309. doi: 10.1164/ajrccm/148.2.304. [DOI] [PubMed] [Google Scholar]
  41. Whyte K. F., Flenley D. C. Can pulmonary vasodilators improve survival in cor pulmonale due to hypoxic chronic bronchitis and emphysema? Thorax. 1988 Jan;43(1):1–8. doi: 10.1136/thx.43.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Winter R. J., Zhao L., Krausz T., Hughes J. M. Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am Rev Respir Dis. 1991 Dec;144(6):1342–1346. doi: 10.1164/ajrccm/144.6.1342. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES